Millennium Management
CDAK

Millennium Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Millennium Management’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-161,957
Closed -$28K – 7125
2023
Q1 		$28K Sell
161,957
-138,854
-46% -$77.3K ﹤0.01% 5787
2022
Q4 		$120K Sell
300,811
-53,160
-15% -$35K ﹤0.01% 5514
2022
Q3 		$277K Buy
353,971
+202,600
+134% +$425K ﹤0.01% 5442
2022
Q2 		$436K Buy
151,371
+115,103
+317% +$404K ﹤0.01% 5076
2022
Q1 		$227K Buy
+36,268
New +$228K ﹤0.01% 5761
2021
Q2 		– Sell
-38,399
Closed -$579K – 7324
2021
Q1 		$579K Buy
38,399
+31,795
+481% +$691K ﹤0.01% 4706
2020
Q4 		$213K Buy
+6,604
New +$87.4K ﹤0.01% 4769

Millennium Management's CDAK Position: Q2 2023 in Review

Millennium Management sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 161,957 shares — an estimated $28K sold.

Millennium Management first reported a position in CDAK in Q4 2020 and held it in 7 quarters. The position peaked at $579K in Q1 2021. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Millennium Management reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Millennium Management sold 161,957 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $28K.
  • Millennium Management first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Millennium Management's Codiak BioSciences, Inc. Common Stock position peaked at $579K in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.